Evidence map›Paper›PMID 38086983›Full record

ArticlePediatric nephrology (Berlin, Germany)2024

Compassionate use of roxadustat for treatment of refractory renal anemia in an infant.

Yan Yang, Yan Chen, Yang Yang, Haitao Bai, Bizi He, Dengli Liu

Open access · hybridAbstract readCase Reports
PubMed Full text at PMC Publisher
In one paragraph

Article in Pediatric nephrology (Berlin, Germany), 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
0.9field-weighted citation impact, top 21% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed, 3 citations in OpenAlex.

  1. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

6 authors at 1 institution in 1 country.

Yan YangDepartment of Pediatrics, The First Affiliated Hospital of Xiamen University, Xiamen, Fujian, China.ORCID 0009-0000-8412-7065
Yan ChenDepartment of Pediatrics, The First Affiliated Hospital of Xiamen University, Xiamen, Fujian, China.
Yang YangDepartment of Pediatrics, The First Affiliated Hospital of Xiamen University, Xiamen, Fujian, China.
Haitao BaiDepartment of Pediatrics, The First Affiliated Hospital of Xiamen University, Xiamen, Fujian, China. baihaitao@163.com.
Bizi HeDepartment of Pediatrics, The First Affiliated Hospital of Xiamen University, Xiamen, Fujian, China.
Dengli LiuDepartment of Pediatrics, The First Affiliated Hospital of Xiamen University, Xiamen, Fujian, China.
Xiamen University · CN

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

backgroundErythropoiesis-stimulating agents (ESAs) have played an important role in the treatment of renal anemia in children, but cannot improve hemoglobin to target level in some cases. Roxadustat, a hypoxia-inducible factor prolyl hydroxylase inhibitor, can stimulate endogenous erythropoietin production and regulate iron metabolism even in patients with kidney failure. However, roxadustat has not yet been approved for use in children. CASE-DIAGNOSIS/TREATMENT: We report a case of refractory renal anemia in an 80-day-old boy, who was hyporesponsive to ESAs even in combination with iron supplementation and transfusion. Compassionate use of roxadustat successfully corrected the intractable anemia. Hyperkalemia is a manageable adverse event of concern during follow-up.

conclusionThe successful experience in this case may inform the clinical utility of roxadustat for refractory renal anemia in children, which should be further confirmed by well-designed prospective clinical trials.

Indexed as

AnemiaHematinicsRenal Insufficiency, ChronicChildChronic DiseaseCompassionate Use TrialsGlycineHumansIronIsoquinolinesMaleProspective StudiesGlycineHematinicsIronIsoquinolinesAnemiaChronic kidney diseaseErythropoiesis-stimulating agentHypoxia-inducible factor prolyl hydroxylase inhibitorInfantRoxadustat

Identifiers

PMID38086983
PMCPMC10817834
OpenAlexW4389683931

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.